Original Research Article

Efficacy of intraliesional bleomycin in treatment of lymphangiomas in children: an observational study

Arun M. Ainippully, Ranjit P.*, Arun Preeth V., Prathap S.

Department of Pediatric Surgery, Government Medical College, Kozhikode, Kerala, India

Received: 10 November 2017
Accepted: 09 December 2017

*Correspondence:
Dr. Ranjit P.,
E-mail: itzranjit@gmail.com

ABSTRACT

Background: Lymphangioma, a benign slow growing tumor of lymphatic vessels, common to the pediatric age group usually presents as swelling with cosmetic deformity. Commonly affecting the head and neck region it may present with compressive symptoms like airway obstruction or dysphagia. Previously surgical excision was the treatment of choice but it involves significant risks and so sclerotherapy has gained popularity. We conducted this prospective observational study to have a quantitative analysis of the effect of intraleralessional bleomycin in reducing the size of lymphangiomias in children in our setup.

Methods: This observational study was conducted in the paediatric surgery department between 2014 and 2016. A total of 34 children who presented with swellings which were diagnosed to be lymphangiomas based on clinical and sonological basis were included in the study and underwent intraleralessional bleomycin sclerotherapy. Details like dimensions of the lesion before and after the treatment, ultrasound measurement, residual size, characteristic of the cyst like presence or absence of septation, micro or macrocytic were recorded along with demographic details like age and sex. Outcome after 4 weeks was evaluated and classified into 3 groups as in excellent response, good response or poor response. Statistical analysis was done using R statistical software.

Results: Of the 34 patients 59% were males. The median age was 18 months with inter-quartile range 4-36 months. 88% of patients had macrocystic lesions. 4 weeks after bleomycin sclerotherapy excellent response was seen in 23 (68%) of the patients, good in 8 (26%) and poor in 3 (9%) of the patients. There was statistically significant association between post procedure swelling, type of cysts and presence of septations and the number of sittings required to the outcome (p value <0.05).

Conclusions: Present study shows that intraleralessional bleomycin sclerotherapy is very effective in the treatment of lymphangiomias in children, with macrocystic lesions showing a significantly better response.

Keywords: Bleomycin, Paediatric lymphangioma, Sclerotherapy

INTRODUCTION

Lymphangioma is a benign slow growing tumor of lymphatic vessels, the most frequent site being in the head and neck region,axillla and rarely in the mediastinum. This tumor is usually confined to the pediatric age group. However, it has been reported in adults as well. It manifests at birth in up to 65% of cases and presents by 2nd year of life in 80-90% of cases.

The reported incidence of lymphangioma is 1.5 to 2.8 per 1000 across both gender and all races. The common presentation of these lesions is swelling and cosmetic deformity. In addition, a swelling of significant size can
compress vital structures and cause airway obstruction, dysphagia, speech abnormalities.4,5

Previously, surgical excision was the treatment of choice.6 Other options are radiation therapy and incision and drainage, with unsatisfactory results. As the lesion infiltrates the tissue planes and encircles the neurovascular structures, complete surgical extirpation is not a viable option in many cases.7 Moreover, Recurrences, scar formation and nerve injuries are common complications following surgery.1,2

Intralesional sclerotherapy has gained popularity as an acceptable method of treatment for lymphangiomas in children with more effectiveness in macro cystic lesions.1,8-11 Injection sclerotherapy produces irritation of endothelial lining of the lymphangiomas which leads to inflammation and fibrosis eventually leading to involution.

There has been little quantitative analysis of the effect of intralesional injection of bleomycin in our setup. This prospective observational study was conducted to find out the effect of intralesional bleomycin injection of bleomycin in reducing the size of lymphangioma in children.

METHODS

We conducted this prospective observational study at the department of pediatric surgery at government medical college kozhikode from 2014 to 2016. All consecutive patients satisfying the inclusion criteria were recruited into the study. We selected only those patients with age less than 12 years who presented with swelling diagnosed as lymphangioma based on clinical and ultrasound imaging. Only those patients with lesion containing straw-colored serous fluid on aspiration were included in the study. We excluded swellings with size less than 2 cm. Moreover, Post surgical recurrent lesions were also excluded from the study. We studied 34 patients in total. Using a predesigned and pretested data collection form, we collected demographic variables like age, sex, body weight, height. In addition, we recorded other details like size of the lesion before and after the treatment, ultrasound measurement, residual size, characteristic of the cyst like presence or absence of septation, micro or macrocytic and outcome in terms of excellent, good or bad.

Under sedation and local anesthesia and with strict aseptic precautions, the cyst was aspirated with a 18G needle. While keeping the tip of the aspiration cannula within the cyst lumen, 0.5 IU per Kg body weight of Bleomycin was injected. The calculated dose was diluted with distilled water. If multiple septations were detected on pre procedure ultrasound evaluation, the drug was injected into different cysts separately. Patients were observed for 24 hours post procedure and observed for any immediate complications. Response was recorded after four weeks after the procedure clinically and with ultrasound measurements. This procedure was repeated after four weeks if the cystic component persisted and measured greater than 1 cm cube volume. No further attempts were made if there was a poor response to two sittings of procedure.

The response was graded based on clinical appearance and the volume reduction as per ultrasound into three categories.

- **Excellent response:** no obvious swelling clinically and USG showing no residual lesion or residual solid lesion or if residual cystic lesion a volume reduction >80% in size with single/multiple doses of neomycin.
- **Good response:** Clinically obvious swelling but with significant reduction in size clinically and with reduction in volume on USG >50% but less than 80% with multiple sittings.
- **Poor response:** Minimal change in size clinically after two sittings.

We had obtained institutional ethics committee clearance before conducting and recruiting patients. Informed consents were taken from parents and assent from the patients.

**Statistical analysis**

Statistical analysis was done in R software. We summarized continuous data as mean (±) and standard and categorical data as proportions. Associations were studied with chi-square test. Before and after measurements were compared with paired T test. During analysis, wherever missing data was present. We considered only complete cases for analysis. Statistically, significance was taken as p value <0.05.

**RESULTS**

Out of the 34 patients in present study, there was a male preponderance with 20 (59%) constituting the males. The median age was 18 months (IQR 4-36).

**Table 1: Demographic features.**

| (ALL) N=34 |  |
|---|---|
| Age | 18.0 (4.25; 34.5) |
| Gender |  |
| Female | 14 (41.2%) |
| Male | 20 (58.8%) |
| Site |  |
| Axilla | 3 (8.82%) |
| Chest wall | 3 (8.82%) |
| Face | 1 (2.94%) |
| Limb | 2 (5.88%) |
| Neck | 25 (73.5%) |
The mean size of the swelling was 6 cm X 5cm (±3X2). The median volume on sonological evaluation was 25 (IQR 15-35). The most common site affected was neck with 25 (74%) affected with face being the least affected (Table 1).

The post procedure result was excellent in 23(68%) of the patients, good in 8(26%) and poor in 3 (9%) of the patients. No other symptoms were present in 94 % of the patients.

### Table 2: Baseline comparison of demographic features.

|                | (ALL) N=34 | Excellent N=23 | Good N=8 | Poor N=3 | p overall |
|----------------|------------|----------------|----------|----------|-----------|
| Age            | 18.0 (4.25;34.5) | 18.0 (4.00;30.0) | 14.5 (9.50;39.0) | 72.0 (37.0;84.0) | 0.581     |
| Length Clinical| 6.00 (5.00;7.00)  | 6.00 (4.00;6.00)  | 6.00 (5.00;7.25)  | 7.00 (6.00;9.50)  | 0.378     |
| Breadth Clinical| 4.00 (4.00;6.75)  | 4.00 (3.50;5.00)  | 5.00 (4.00;7.00)  | 4.00 (4.00;6.50)  | 0.773     |
| USG volume in cc| 25.0 (16.2;35.0)  | 25.0 (15.0;35.0)  | 32.5 (18.8;37.5)  | 35.0 (27.5;40.0)  | 0.668     |
| Length Post    | 2.73 (2.28) .(.)  | 1.50 (0.53) 6.00 (1.73) <0.001 |
| Breadth Post   | 2.18 (2.40) .(.)  | 1.12 (0.35) 5.00 (3.46) 0.007 |
| USG Residual   | 21.8 (10.4) .(.)  | 12.0 (. ) 25.0 (10.0) 0.377 |
| Gender         |             |                |           |          | 0.155     |
| Female         | 14 (41.2%)   | 12 (52.2%)     | 1 (12.5%) | 1 (33.3%) |           |
| Male           | 20 (58.8%)   | 11 (47.8%)     | 7 (87.5%) | 2 (66.7%) |           |

### Table 3: Association between various factors and outcome.

|                | (ALL) N=34 | E N=23 | G N=8 | P N=3 | p overall |
|----------------|------------|--------|-------|-------|-----------|
| No. of sittings|             |        |       |       | <0.001    |
| 1              | 20 (58.8%)  | 19 (82.6%) | 0 (0.00%) | 1 (33.3%) |           |
| 2              | 12 (35.3%)  | 4 (17.4%)  | 7 (87.5%) | 1 (33.3%) |           |
| 3              | 2 (5.88%)   | 0 (0.00%)  | 1 (12.5%) | 1 (33.3%) |           |
| Site           |             |        |       |       | 0.088     |
| Axilla         | 3 (8.82%)   | 3 (13.0%)  | 0 (0.00%) | 0 (0.00%) |           |
| Chest          | 3 (8.82%)   | 2 (8.70%)  | 0 (0.00%) | 1 (33.3%) |           |
| Face           | 1 (2.94%)   | 0 (0.00%)  | 1 (12.5%) | 0 (0.00%) |           |
| Limbs          | 2 (5.88%)   | 0 (0.00%)  | 2 (25.0%) | 0 (0.00%) |           |
| Neck           | 25 (73.5%)  | 18 (78.3%) | 5 (62.5%) | 2 (66.7%) |           |
| Other symptoms |             |        |       |       | 0.005     |
| Absent         | 32 (94.1%)  | 23 (100%)  | 8 (100%)  | 1 (33.3%) |           |
| present        | 2 (5.88%)   | 0 (0.00%)  | 0 (0.00%) | 2 (66.7%) |           |
| Macro/Micro    |             |        |       |       | <0.001    |
| Macrocytic     | 30 (88.2%)  | 23 (100%)  | 7 (87.5%) | 0 (0.00%) |           |
| Microcytic     | 4 (11.8%)   | 0 (0.00%)  | 1 (12.5%) | 3 (100%)  |           |
| Septations     |             |        |       |       | <0.001    |
| Absent         | 19 (55.9%)  | 18 (78.3%) | 1 (12.5%) | 0 (0.00%) |           |
| Present        | 15 (44.1%)  | 5 (21.7%)  | 7 (87.5%) | 3 (100%)  |           |
| Post procedure swelling |         |        |       |       | <0.001    |
| Absent         | 23 (67.6%)  | 23 (100%)  | 0 (0.00%) | 0 (0.00%) |           |
| Present        | 11 (32.4%)  | 0 (0.00%)  | 8 (100%)  | 3 (100%)  |           |

Most of the patients (88%) presented with macrocytic swellings.

Septations were present in 44% of the patients. Of the patients who underwent the procedures, only 11 (32%) had residual swellings. Baseline comparison of various demographic features across the outcome group is given in Table 2. There was a statistically significant difference between the breadth of the swelling before and after the study (Table 2). The mean difference was 3.27cm (CI 4.7-1.8). Similarly, there was a statistically significant difference between the length of the swelling before and after the study (Table 2).
number of sittings and outcome with patients with poor outcome requiring more sittings (Table 3).

**DISCUSSION**

The purpose of this study to determine whether intralesional injection sclerotherapy with bleomycin is effective in treating the lymphangioma in the pediatric age group. The result from the study showed that the outcome was excellent in the majority of the patients. There was a reduction in the overall size of the swelling before and after the injection of intralesional bleomycin. There was excellent response in majority of the patients. Both sonological and clinical assessment confirmed this. There was a statistically significant difference in the measurements both clinically and sonologically.

The reduction in size could be due to aspiration of the fluid. Thereafter, the sacrosanct injected would have caused apposition of the collapsed walls thereby reducing the overall size. Simple aspiration alone will result in recurrence. However, in present study, the follow-up result showed an excellent outcome in the majority of the patients. Several studies using bleomycin as an intrallesional sclerosant have shown favorable results compared to surgery. Tanigawa N et al described the effective use of bleomycin fat emulsion for treatment of cystic hygromas. In a study by Orford et al, intrallesional bleomycin showed an excellent response in 44% and good response in another 44% of patients with minor transient side effects. Studies conducted in Malaysia showed complete resolution in 63% where as 21% showed good response. 66% of children showed a complete response with only 11% needing a second sitting for resolution.

A retrospective study with intrallesional bleomycin showed a complete response in 63% of children with a good response in 21% and poor response in 16% without any serious side effect or complication. Most authors have quoted success rates of between 36 to 63% for complete tumor regression and up to 88% for significant lesion regression without significant side effects. Poor response varied between 12 -23%. Most published data show a good response to macrocystic forms of lymphangiomas. In the present study, 68% of the patients showed an excellent outcome. The increased proportion of macrocystic swellings in present study could explain the better results compared to the reported response rate in other studies in the literature.

One of the limitations in present study is the low sample size and its observational nature. In addition, there were lost to follow up and missing data in present study. Properly designed randomized controlled trial s will address the limitations in the present study.

Present study has shown there is excellent response rate for macrocystic swellings. Moreover, multiple sittings are needed for swelling presented with poor outcomes.

**ACKNOWLEDGEMENTS**

Authors would like to thank Dr. Jeo Tharakan and Dr. Sarath KN for support of the study.

**Funding: No funding sources**

**Conflict of interest: None declared**

**Ethical approval: The study was approved by the Institutional Ethics Committee**

**REFERENCES**

1. Cuervo JL, Galli E, Eisele G, Johannes E, Fainboim A, Tonini S, et al. Lymphatic malformations: percutaneous treatment with bleomycin. Arch Argent Pediatr 2011;109(5):417-22.
2. Vlahovic A, Gazikalovic A, Adjic O. Bleomycin sclerotherapy for lymphatic malformation after unsuccessful surgical excision: case report. Acta Otorhinolaryngol Ital. 2015;35(5):365-7.
3. Sandlas G, Kothari P, Karkera P, Gupta A. Bleomycin: A worthy alternative. Indian J Plast Surg. 2011;44(1):50-3.
4. Hamoir M, Remacle M, Youssif A, Moulin D, Francois G, Claus D, et al. Surgical management of parapharyngeal cystic hygroma causing sudden airway obstruction. Head Neck Surg. 1988;10(6):406-10.
5. Ricciardelli EJ, Richardson MA. Cervicofacial cystic hygroma. Patterns of recurrence and management of the difficult case. Arch Otolaryngol Head Neck Surg. 1991;117(5):546-53.
6. Khali U, Fatimi SH, Saleem T. Giant unresectable lymphangioma of the trunk managed via intra-tumour injections of bleomycin. J Pak Med Assoc. 2010;60(7):605-7.
7. Sung MW, Chang SO, Choi JH, Kim JY. Bleomycin sclerotherapy in patients with congenital lymphatic malformation in the head and neck. Am J Otolaryngol. 1995; 16(4): 236-41.
8. Zulfiqar MA, Zaleha AM, Zakaria Z, Amin T. The treatment of neck lymphangioma with intrallesional injection of bleomycin. Med J Malaysia. 1999;54(4):478-81.
9. Mathur NN, Rana I, Bothra R, Dhawan R, Kathuria G, Pradhan T. Bleomycin sclerotherapy in congenital lymphatic and vascular malformations of head and neck. Int J Pediatr Otorhinolaryngol. 2005;69(1):75-80.
10. Rozman Z, Thambidorai RR, Zaleha AM, Zakaria Z, Zulfiqar MA. Lymphangioma: Is intrallesional bleomycin sclerotherapy effective? Biomed Imaging Interv J. 2011;7(3):e18.
11. Chaudry G, Guevara CJ, Rialon KL, Kerr C, Mulliken JB, Greene AK, et al. Safety and efficacy of bleomycin sclerotherapy for macrocystic lymphatic malformation. Cardiovasc Intervent Radiol. 2014;37(6):1476-81.
12. Tanigawa N, Shimomatsu T, Takahashi K, Inomata Y, Tanaka K, Satomura K, et al. Treatment
of cystic hygroma and lymphangioma with the use of bleomycin fat emulsion. Cancer. 1987;60(4):741-9.
13. Orford J, Barker A, Thonell S, King P, Murphy J. Bleomycin therapy for cystic hygroma. J Pediatr Surg. 1995;30(9):1282-7.
14. Baskin D, Tander B, Bankaoglu M. Local bleomycin injection in the treatment of lymphangioma. Eur J Pediatr Surg. 2005;15(6):383-6.
15. Yang Y, Sun M, Ma Q, Cheng X, Ao J, Tian L et al. Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations. J Vasc Surg. 2011;53(1):150-5.

Cite this article as: Ainippully AM, Ranjit P, Preeth AV, Prathap S. Efficacy of intrallesional bleomycin in treatment of lymphangiomas in children: an observational study. Int Surg J 2018;5:238-42.